HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)
Grant Amount: Unspecified.
Three decades into the epidemic, HIV/AIDS in the U.S. continues to evolve, and the role of drug abuse in fueling the epidemic has also evolved. Despite progress in HIV/AIDS treatment and prevention and reductions in HIV/morbidity and mortality, HIV/AIDS health disparities remain a challenge that must be addressed. This announcement encourages research to identify the role(s) that drug abuse plays in fueling the epidemic in vulnerable groups and to develop effective interventions to prevent new infections and to improve the health and well-being of those living with HIV/AIDS. To do this, it is essential that research be directed toward understanding the factors (biological, behavioral, psychosocial, environmental, institutional, etc.) responsible for the profoundly disproportionate burden of HIV/AIDS among vulnerable groups (racial/ethnic minorities, sexual minorities, youth) in the United States.
This Funding Opportunity Announcement (FOA) will support studies in vulnerable populations to: (1) understand the contribution of drug abuse (both injection and non-injection) to the acquisition and/or transmission of HIV; (2) study disease progression and disease outcomes in drug using populations; (3) develop and/or improve prevention and treatment interventions, particularly comprehensive, integrated interventions; (4) improve the availability, delivery and quality of evidence-based prevention and treatment services across a variety of settings; and (5) address organizational, structural, and/or community level factors including social, drug-using, and sexual networks associated with health disparities.
A range of methodological approaches including basic, clinical, epidemiological, prevention, and treatment research as well as multidisciplinary studies are needed to address the complex interplay of biomedical, behavioral, and social factors that lead to HIV/AIDS disparities among vulnerable populations.
National Institute on Drug Abuse
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Application Due Date
Project Start Date
Grants.gov Customer Support , Phone: (800) 518-4726
Drug Abuse Health Care Programs/Services HIV/AIDS Prevention Medical Treatments and Therapies Men Who Have Sex with Men Minorities Research Programs
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Companion Funding Opportunity: PA-12-281, R01 Research Project Grant.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.